IGC PHARMA, INC.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|
| Revenue | $580.4K | $6.4M | $7.7M | $2.3M | $8.0M | $4.2M | $4.1M |
| Cost of Revenue | $362.1K | $5.5M | $7.1M | $1.9M | $6.5M | $4.8M | $3.9M |
| Gross Profit | $218.2K | $843.3K | $579.7K | $381.6K | $1.5M | $-618.4K | $159.3K |
| Gross Margin | 37.6% | 13.2% | 7.5% | 16.8% | 19.1% | -14.7% | 3.9% |
| Operating Expenses | |||||||
| Research & Development | — | — | — | — | — | — | — |
| SG&A Expense | $2.3M | $2.7M | $4.1M | $2.2M | $3.0M | $4.7M | $7.3M |
| Operating Income | $-2.1M | $-2.9M | $-4.3M | $-2.5M | $-2.5M | $-7.5M | $-15.9M |
| Operating Margin | -354.0% | -45.6% | -56.5% | -111.2% | -30.9% | -178.9% | -390.0% |
| Interest Expense | $223.5K | $213.9K | $286.3K | $291.5K | $419.4K | $984.0K | $1.4M |
| Pretax Income | $-1.8M | $-2.8M | $-4.7M | $-3.0M | $-2.6M | $-7.7M | $-16.9M |
| Income Tax Expense | $14.4K | $579 | $5.2K | $0 | $-365.1K | $172.8K | $4.1M |
| Net Income | $-1.9M | $-2.8M | $-4.6M | $-3.0M | $-2.3M | $-7.8M | $-20.2M |
| Net Margin | -321.7% | -44.1% | -60.1% | -133.0% | -28.0% | -184.6% | -496.8% |
| EPS (Basic) | $-0.07 | $-0.17 | $-0.31 | $-0.37 | $-0.32 | $-1.33 | $-0.67 |
| EPS (Diluted) | $-0.07 | $-0.17 | $-0.31 | $-0.37 | $-0.32 | $-1.33 | $-0.67 |
| Shares Outstanding (Basic) | 25.7M | 16.4M | 14.8M | 8.2M | 7.0M | 5.8M | 30.2M |
| Shares Outstanding (Diluted) | 25.7M | 16.4M | 14.8M | 8.2M | 7.0M | 5.8M | 30.2M |
| Dividends Per Share | — | — | — | — | — | — | — |